STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Relatório de Atividades 2025 – Brasil
Mais Dados Mais Saúde – Percepções da população brasileira sobre fatores de risco…
What Primary Care Records Reveal About Cancer Signs and Symptoms
O que os prontuários da atenção primária revelam sobre sinais e sintomas de…
CRVS Performance Measurement and Monitoring Resource Kit
Model Kentucky Ordinance Establishing a County Opioid Abatement Advisory Council
The invisible pain: Gaps in Brazil’s public health system data on Menstrual and…
Exploring the Interface Between Birth Registration and Citizenship Determination: A Scoping Study in…
A dor invisível: lacunas nos dados do SUS sobre dor menstrual e pélvica
Catalyzing Support for CRVS Improvement – Examples from the Data for Health Initiative